Adagio Medical explores strategic options, cuts workforce

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) has initiated a formal process to explore strategic alternatives, including a possible acquisition, merger, or business combination, according to a press release from the company.

The board of directors completed a review of the company's business and resources before launching the process. In connection with the decision, Adagio Medical is implementing a workforce reduction to align its cost structure with its prioritized programs. No timetable has been set for the evaluation, and the company said it does not intend to disclose further developments unless required.

As of June 30, 2026, the company held approximately $7.7 million in cash, cash equivalents, and investments in marketable securities, on a preliminary unaudited basis.

Adagio Medical said it will continue to advance its Premarket Approval application for its vCLAS Ventricular Ablation System with the U.S. Food and Drug Administration. The company submitted results from its FULCRUM-VT pivotal study to the FDA in May 2026. The vCLAS system is CE Marked and commercially available in Europe and select other markets, but remains limited to investigational use in the United States.

You May Also Be Interested In

• Zephyr Minerals closes $260,000 non-brokered private placement
• Lion Copper extends debenture maturity and hires equity research firm
• eBay to cut 9% of workforce in strategic operational push, Reuters reports